MSD

News

Padcev/Keytruda scores again in early bladder cancer

Pfizer and Astellas now have two studies supporting the use of Padcev with MSD's Keytruda as perioperative therapy for muscle-invasive bladder cancer.

News

Are RSV shots next in line for restrictions in the US?

After pushing for restrictions on vaccines for COVID-19 and hepatitis B, the Trump administration seems to be turning its attention to RSV shots.

News

Setback for MSD as German court blocks Keytruda SC launch

A court in Germany has granted an injunction that will prevent MSD from distributing the new, subcutaneous version of its cancer drug Keytruda.

News

EMA starts review of 'transformative' bladder cancer therapy

The EMA has started a review of a regimen based on Pfizer/Astellas' Padcev and MSD's Keytruda that is described as a game-changer for bladder cancer.

News

Update: MSD's $9.2bn deal for flu biotech Cidara confirmed

MSD has signed a $9.2 billion takeover deal for Cidara that will bolt on a universal flu prevention candidate in phase 3.

Market Access

City View of London around Liverpool Street

FT Summit: How Is U.S. Policy Reshaping the UK and EU Pharma...

For the Financial Times (FT) Global Pharma & Biotech Summit in London 2025, pharmaphorum is providing coverage courtesy of NAVLIN Daily.

Padcev/Keytruda scores again in early bladder cancer

Are RSV shots next in line for restrictions in the US?

Setback for MSD as German court blocks Keytruda SC launch

EMA starts review of 'transformative' bladder cancer therapy

Update: MSD's $9.2bn deal for flu biotech Cidara confirmed

FT Summit: How Is U.S. Policy Reshaping the UK and EU Pharma...

EMA seeks input on virtual alternative to animal test

Using AI-driven synthetic personas to take your insights fur...

MSD

Editor's Picks